Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib cardiac repolarization study in advanced solid tumors
NCT03042910Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in solid tumor, sponsored by Pfizer. Primary endpoints: Time-matched Mean Change From Baseline in Corrected QT Intervals Based on the Fridericia's Correction Fomulation (QTcF) at Day 22, Intercept of Predicted Linear Mixed Effects Models for Change From Baseline in QTcF Versus Plasma Talazoparib Concentrations at Day 22 and 1 more. Started Oct 2016; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03042910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042910.